



Attorney Docket No.: 115P002D

#3/IDS

KD 7/12/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:

EDMUND Y.M. CHEIN

Application No.: 09/782,015

Filed: February 12, 2001

For: **A METHOD OF HORMONE
TREATMENT FOR PATIENTS WITH
SYMPTOMS CONSISTENT WITH
MULTIPLE SCLEROSIS**

Art Group: 1653

Examiner: Unknown

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to Rule 1.97, Applicant desires to make of record the reference(s) set forth on the attached Form PTO 1449. A copy of each reference is submitted herewith.

It is hereby stated that this Information Disclosure Statement is being filed prior to the issuance of the initial office Action, therefore no petition or fee is required. However, in the event a petition is needed for consideration of this Information Disclosure Statement, Applicant hereby so petitions. Please charge any additional fee due to Deposit Account 02-2666.

Respectfully submitted,

BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP

William Thomas Babbitt, Reg. No. 39,591

Date: 6/28/01

12400 Wilshire Blvd., 7th Floor
Los Angeles, California 90025
Telephone: (310) 207-3800

CERTIFICATE OF MAILING


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 to the Patent and Trademark Office on: June 28, 2001

Margaux Rodriguez

June 28, 2001

Date

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4 Attorney Docket Number 000115-P002D

Digitized by srujanika@gmail.com

U.S. PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box→



JUL 03 2001

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Patent Number	09/782015
Sheet	2	of	4	Issue Date	February 12, 2001
				First Named Inventor	Edmund Y.M. Chein
				Group Art Unit	1653
				Examiner Name	
				Attorney Docket Number	000115-P002D

RECEIVED
JUL 05 2001
TECH CENTER 1600/290

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


Exam. Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	KLATZ, et al., Can We Grow Young? Parade Magazine, April 20, 1997, pp. 20-23.	
	4	HODES, The NIA's Position on Growth Hormone Replacement Therapy in Adults, Journal of American Geriatrics Society, 1994, Vol. 42, pp. 1208-1211, comments by Edmund Chein, December 1997.	
	5	CRANTON, et al., Growth Hormone to Reverse Aging, Alternative Medicine, June 1995, (4 pages).	
	6	Human Growth Hormone - The Controversy Continues, Muscle & Fitness, December 1995, pp. 262-265.	
	7	KLATZ, The War on Aging Has Begun, American Academy of Anti-Aging Medicine,	
	8	RUSH, Miraculous hormones so you always have the body of a twenty year old, Cosmopolitan (En Espanol), August 1996 (4 pages).	
	9	CAREY, The Latest Anti-Aging Drug is Cheap, Convenient, and Makes You Feel Like a Kid Again. So Why Aren't We All Taking It? Hippocrates: Health & Medicine for Physicians, February 1996, pp. 69-74.	
	10	LANZ, The Fountain of Youth? Ability, 1996, Vol. 96, Issue 12.	
	11	CRANTON, et al., Resetting the Clock, M. Evans and Company, Inc., New York, NY, 1996, pp. 228-233.	
	12	REGELSON, et al., The Superhormone Promise, Nature's Antidote to Aging, Simon & Schuster, New York, NY, 1996, pp. 24-27.	
	13	Life Extension, June 1997.	
	14	JORGENSEN, et al., Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance, European Journal of Endocrinology, 1994, pp. 224-228.	
	15	HOFFMANN, et al., Growth Hormone Therapy in the Elderly: Implications for the Aging Brain, Psych. Endocrinology, Vol. 17, No. 4, pp. 327-333, 1992, Pergamon Press Ltd.	
	16	CAREY, The Latest Anti-Aging Drug is Cheap, Convenient, and Makes You Feel Like a Kid Again. So Why Aren't We All Taking It? Health, November-December 1995, pp. 69-74.	
	17	SCOW, et al., Effect of Testosterone Propionate and Growth Hormone on Growth and Chemical Composition of Muscle and Other Tissues in Hypophysectomized Male Rats, The Endocrine Society, 1965, pp. 852-858, J.B. Lippincott Company.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box→



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB#051-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Patent Number	09/782015
Issue Date	February 12, 2001
First Named Inventor	Edmund Y.M. Chein
Group Art Unit	1653
Examiner Name	

Sheet 3 of 4 Attorney Docket Number 000115.P002D

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam. Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	18	JORGENSEN, et al., Beneficial Effects of Growth Hormone Treatment in GH-Deficient Adults, The Lancet, June 3, 1989, pp. 1221-1225,	
	19	CHRISTIANSEN, et al., GH-Replacement Therapy in Adults, Horm Res, 1991, pp. 66-72, S. Karger AG, Basel, Switzerland.	
	20	CHRISTIANSEN, The different routes of administration and the effect of hormone replacement therapy on osteoporosis, Fertility and Sterility, 1994 The American Fertility Society, Vol. 62 (Suppl. 2), No. 6, December 1994, pp. 152S-156S.	
	21	JORGENSEN, et al., Long-term growth hormone treatment in growth hormone deficient adults, Acta Endocrinologica, 1991, pp. 449-453, Copenhagen, Denmark.	
	22	CHRISTIANSEN, et al., Beneficial effects of GH replacement therapy in adults, Acta Endocrinologica, 1991, pp. 7-13, Copenhagen, Denmark.	
	23	MOILER, et al., Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters, Clinical Endocrinology, 1993, pp. 403-408, Denmark.	
	24	SHOHAM, et al., Cotreatment with growth hormone for induction of spermatogenesis in patients with hypogonadotropic hypogonadism, The American Fertility Society, 1992, pp. 1044-1051, Vol. 57, No. 5, May 1992.	
	25	CUNEO, et al., Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength, The American Physiological Society, 1991, pp. 688-694.	
	26	MORALES, et al., The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women, Clinical Endocrinology, 1998, pp. 421-432, Blackwell Science Ltd.	
	27	CUNEO, et al., Growth Hormone Treatment Improves Serum Lipids and Lipoprotein in Adults With Growth Hormone Deficiency, Metabolism, Vol. 42, No. 12, December 1993, pp. 1519-1523.	
	28	PARRA, et al., Body Composition in Hypopituitary Dwarfs Before and During Human Growth Hormone Therapy, Metabolism, Vol. 28, No. 8, August 1979, pp. 851-857.	
	29	JOHANSSON, et al., Two Years of Growth Hormone (GH) Treatment Increases Bone Mineral Content and Density in Hypopituitary Patients with Adult-Onset GH Deficiency, Journal of Clinical Endocrinology and Metabolism, 1996, Vol. 81, No. 8, pp. 2865-2873.	
	30	GIBNEY, et al., The Effects of 10 Years of Recombinant Human Growth Hormone (GH) in Adult GH-Deficient Patients, The Journal of Clinical Endocrinology & Metabolism, Vol. 84, No. 8, 1999, pp. 2596-2602.	
	31	BOURGUIGNON, et al., Pubertal Growth and Final Height in Hypopituitary Boys: A Minor Role of Bone Age at Onset of Puberty, Journal of Clinical Endocrinology and Metabolism, Vol. 63, pp. 376-382.	

Examiner Signature


Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box→

1



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB05-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
If this form contains information which it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known

Patent Number	09/782015
Issue Date	February 12, 2001
First Named Inventor	Edmund Y.M. Chein
Group Art Unit	1653
Examiner Name	
Attorney Docket Number	000115.P002D

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.